AgingResearch.NewsJoin free

Pharvaris

CompanySwitzerland

Pharvaris develops one asset, in phase 3 (deucrictibant in hereditary angioedema). Mostly small molecule acting on BDKRB2; based in Switzerland.

1
Asset
Furthest stage
Phase 3
0
Trials
1
Signal

Pipeline

1

  • deucrictibant

    Blocks bradykinin B2 receptors to relieve bradykinin-mediated angioedema attacks.

    Phase 3, Small molecule, BDKRB2, hereditary angioedema

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1

Intelligence